OCUP - Ocuphire initiates mid-stage trial of APX3330 in diabetic retinopathy

Ocuphire Pharma (OCUP) announces that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy ((NPDR)) and mild proliferative diabetic retinopathy ((mild PDR)).The company said that topline data from the study is expected by early 2022.APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1).The ZETA-1 trial is a randomized, placebo-controlled, double-masked study designed to evaluate the efficacy of APX3330 to improve diabetic retinopathy over 24 weeks. The primary endpoint of the study will evaluate the percentage of subjects with a ? 2 step improvement on the Diabetic Retinopathy Severity Scale ((DRSS)) score.The study will be conducted in up to 20 U.S. sites and is expected to enroll about 100 subjects with moderately-severe to severe NPDR or mild PDR in the study eye.A number of retinal centers across the US

For further details see:

Ocuphire initiates mid-stage trial of APX3330 in diabetic retinopathy